Moberg Pharma Q2’21: Progress According to Plan - Redeye

Redeye's initial comment on the Q2 report this morning. We see that Moberg Pharma is progressing as planned. The earlier communicated road map for MOB-15 is unchanged. We do not see any surprises and are encouraged by the confirmation of the progress.

Länk till analysen i sin helhet: https://www.redeye.se/research/818257/moberg-pharma-q221-progress-according-to-plan?utm_source=finwire&utm_medium=RSS